Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Sitagliptin Phosphate × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 5 Diabetes Mellitus, Type 2 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Myelodysplastic Syndromes 2 Leukemia, Myeloid, Acute 2 Thyroid Nodule 1 Renal Insufficiency 1 Pancreatic Neoplasms 1 Neoplasms, Adipose Tissue 1 Multiple Endocrine Neoplasia Type 1 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Kidney Failure, Chronic 1 Insulin Resistance 1 Infertility 1 Glioblastoma 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1 Body Weight 1

Interventions

Trastuzumab 523 Paclitaxel 480 Cyclophosphamide 469 Docetaxel 416 Capecitabine 353 Letrozole 312 Fulvestrant 271 Doxorubicin 246 Tamoxifen 230 Carboplatin 229 Anastrozole 198 Radiotherapy 194 exemestane 187 Epirubicin 171 Bevacizumab 166 palbociclib 151 Lapatinib 146 Vinorelbine 143 pertuzumab 142 Gemcitabine 139 pembrolizumab 137 Surveys and Questionnaires 119 Exercise 112 Magnetic Resonance Spectroscopy 111 eribulin 103 Fluorouracil 102 Albumin-Bound Paclitaxel 100 Blood Specimen Collection 98 130-nm albumin-bound paclitaxel 91 Everolimus 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07436663 2026-02-27

SGLT2i/DPPi

Tanta University

Phase 4 Not yet recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡